The Patented Medicine Prices Review Board welcomes the appointment of Dr. Mitchell Levine of Hamilton, Ont., as the new Chairperson of the Board. The full release is available online. Call 613-288-9664.
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the most recent edition of the Generics360 report, which examines the latest trends in domestic and international generic drug pricing, sales and utilization. The report found that Canada has a strong generics market with the third highest rate of generic drug … Read more
The Patented Medicine Prices Review Board published a scoping paper which provides its initial thoughts on how best to operationalize the Minister of Health’s proposed amendments to the Patented Medicines Regulations, which were published in the Canada Gazette, Part I on December 2, 2017. Health Canada and the PMPRB will be hosting information sessions on the proposed amendments … Read more
Health Minister Ginette Petitpas Taylor (Moncton–Riverview–Dieppe, N.B.) tabled the 2016 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the House of Commons and the Senate. The full release is available online.
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published Alignment Among Public Formularies in Canada – Part 1: General Overview. This is the first report in a three-part series that compares drug coverage across provincial and federal public drug plans. This report compares the lists of drugs covered by … Read more
A Patented Medicine Prices Review Board Hearing Panel issued its decision relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc. The Panel has found that the price of Soliris (eculizumab) 10 mg/mL was and is excessive under sections 83 and 85 of the Patent Act. The Panel has ordered Alexion to … Read more
A new Patented Medicine Prices Review Board report reveals that prescription drug expenditures by Canadian public drug plans reached $11.3-billion in 2015-16, up $1-billion over the previous year. This increase was mainly driven by a 12 per cent growth in drug costs. This relatively high growth rate signals a shift from a sustained period of low growth, as expenditures … Read more
Patented Medicine Prices Review Board Vice-chairperson Dr. Mitchell Levine made the following statement on the launch of Health Canada’s consultation on potential changes to the Patented Medicines Regulations: “The PMPRB welcomes the Minister of Health’s action to strengthen and modernize its pricing framework to reduce the cost of prescription drugs. We look forward to the outcome … Read more
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the first edition of Meds Entry Watch, a new annual publication that provides information on recently launched drugs in Canada and select international markets. This report series is designed to inform decision makers, researchers, and patients of the evolving … Read more
The Patented Medicine Prices Review Board is seeking applicants for membership on the Board by way of open, transparent, and merit-based Governor in Council selection processes for the positions of Chairperson and Board member. Members of the Board are part-time, Governor in Council appointees who preside over hearings into allegations of excessive drug pricing brought by … Read more
